ROSSARI BIOTECH: Q1 EBITDA 806M RUPEES VS 678M (YOY) || Q1 EBITDA MARGIN 11.56% VS 12.5% (YOY)

ROSSARI BIOTECH: Q1 REVENUE 6.97B RUPEES VS 5.43B (YOY)

ROSSARI BIOTECH: Q1 CONS NET PROFIT 351M RUPEES VS 336M (YOY)

SANGAM INDIA: Q1 EBITDA 1.1B RUPEES VS 576M (YOY) || Q1 EBITDA MARGIN 12.3% VS 7.3% (YOY)

SANGAM INDIA: Q1 REVENUE 8.6B RUPEES VS 7.9B (YOY)

SANGAM INDIA: Q1 CONS NET PROFIT 410M RUPEES VS 21M (YOY)

Natco Pharma: Gets Tentative FDA Approval For Olaparib Tablets; Alembic Pharmaceuticals Will Distribute In The U.S.; Expected Sales Of Around $1.4 Billion In The U.S. By March 2026.

JK CEMENT: Q1 EBITDA 6.4B RUPEES VS 6.7B (YOY) || Q1 EBITDA MARGIN 16.5% VS 21.10% (YOY)

JK CEMENT: Q1 REVENUE 38.66B RUPEES VS 31.9B (YOY)

JK CEMENT: Q1 SL NET PROFIT 2.9B RUPEES VS 3.3B (YOY)

HDB Financial: Upcoming Board Meeting Set For July 23 To Consider Fund Raising.

PREMIER POLYFILM: Q1 EBITDA 129M RUPEES VS 91M (YOY) || Q1 EBITDA MARGIN 12.9% VS 12.3% (YOY)

PREMIER POLYFILM: Q1 SL NET PROFIT 91M RUPEES VS 60M (YOY) || Q1 REVENUE 1B RUPEES VS 744M (YOY)

IDBI BANK: Q1 GNPA 2.30% VS 2.32% (QOQ) || Q1 NNPA 0.16% VS 0.15% (QOQ)

IDBI BANK: Q1 SL NET PROFIT 21.15B RUPEES VS 20.1B (YOY)

India Cements: Q1FY27 Cement Sales Realisation Per Ton 3,847 Vs 3,791 (QoQ), 1.5% Increase (QoQ); 3,770 Per Ton (YoY)

India Cements: Aims To Increase Green Power Usage From 6% To 80% By FY29.